United States Health

Takeda Pharmaceutical (NYSE:TAK) signaled on Thursday that it is successfully weathering the peak of its generic competition woes.

Alvotech (NASDAQ:ALVO) has resolved all remaining patent litigation surrounding its biosimilar candidate for the blockbuster eye drug Eylea (aflibercept), reaching a comprehensive global licensing agreement with Regeneron Pharmaceuticals and Bayer AG.

Danaher (NYSE:DHR) reported fourth-quarter results that surpassed Wall Street estimates on Wednesday, providing a bullish outlook for 2026 that suggests the long-awaited recovery in the bioprocessing and life sciences sectors is finally taking hold.

Elevance Health (NYSE:ELV) today reported fourth-quarter and full-year 2025 results that showcased robust top-line growth, even as the company manages shifting dynamics in its Medicaid and Medicare Advantage businesses.

Humana (NYSE:HUM) shares suffered their worst rout in years Tuesday, plunging 20.6% after the Trump administration proposed a nearly flat reimbursement rate for Medicare Advantage plans in 2027, a move that blindsided Wall Street and cast a shadow over the industry’s profit outlook.

Intellia Therapeutics (NASDAQ:NTLA) announced today that the U.S. Food and Drug Administration (FDA) has removed the clinical hold on its MAGNITUDE-2 Phase 3 clinical trial.

HCA Healthcare (NYSE:HCA) delivered a powerful finish to 2025, reporting a 30.6% surge in fourth-quarter net income as the largest U.S. hospital operator capitalized on rising patient demand and stabilized labor costs.

UnitedHealth Group (NYSE:UNH) announced its full-year 2025 results on Tuesday, reporting consolidated revenues of $447.6 billion—a 12% increase year-over-year.

Neurocrine Biosciences (NASDAQ:NBIX) announced on January 26, 2026, the initiation of its Phase 2 clinical study for NBI-1065890, an investigational compound targeting tardive dyskinesia (TD).

Milestone Pharmaceuticals (NASDAQ:MIST) has officially moved into the commercial stage with the U.S. retail launch of Cardamyst™ (etripamil).

SciSparc (NASDAQ:SPRC), a company traditionally focused on cannabinoid-based pharmaceuticals, has officially pivoted into the medical device sector.

Mirum Pharmaceuticals (NASDAQ:MIRM) announced the successful closing of its acquisition of Bluejay Therapeutics, a move that significantly broadens its rare disease pipeline with a potential first-in-class therapy for chronic hepatitis delta virus (HDV).